Citation:Amin A, Blazevski A, Thompson J, Scheltema MJ, Hofman MS, Murphy D, et al 2020
From National Cancer Control Policy
Amin A, Blazevski A, Thompson J, Scheltema MJ, Hofman MS, Murphy D, et al. Protocol for the PRIMARY clinical trial, a prospective, multicentre, cross-sectional study of the additive diagnostic value of gallium-68 prostate-specific membrane antigen positron-emission tomography/computed tomography to multiparametric magnetic resonance imaging in the diagnostic setting for men being investigated for prostate cancer. BJU Int 2020 Apr;125(4):515-524 Available from: http://www.ncbi.nlm.nih.gov/pubmed/31957122.
Critical appraisals